These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 36831367)

  • 1. Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape.
    Mulet-Margalef N; Linares J; Badia-Ramentol J; Jimeno M; Sanz Monte C; Manzano Mozo JL; Calon A
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
    Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
    Front Immunol; 2022; 13():795972. PubMed ID: 35371084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
    Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer.
    Endo E; Okayama H; Saito K; Nakajima S; Yamada L; Ujiie D; Kase K; Fujita S; Endo H; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
    Mol Cancer Res; 2020 Sep; 18(9):1402-1413. PubMed ID: 32493700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy.
    Wu H; Ma W; Jiang C; Li N; Xu X; Ding Y; Jiang H
    Ann Surg Oncol; 2023 Dec; 30(13):8572-8587. PubMed ID: 37667098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficient mismatch repair/microsatellite unstable colorectal cancer: therapeutic advances and questions.
    Cervantes B; André T; Cohen R
    Ther Adv Med Oncol; 2024; 16():17588359231170473. PubMed ID: 38205076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
    Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
    JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting.
    Boutin M; Gill S
    Ther Adv Med Oncol; 2023; 15():17588359231162577. PubMed ID: 37007634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era.
    Shimozaki K; Nakayama I; Hirota T; Yamaguchi K
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
    Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
    Front Immunol; 2022; 13():913483. PubMed ID: 35958603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
    Coutzac C; Bibeau F; Ben Abdelghani M; Aparicio T; Cohen R; Coquan E; Dubreuil O; Evesque L; Ghiringhelli F; Kim S; Lesourd S; Neuzillet C; Phelip JM; Piessen G; Rochigneux P; Samalin E; Soularue E; Touchefeu Y; Tougeron D; Zaanan A; de la Fouchardière C
    Dig Liver Dis; 2022 Oct; 54(10):1335-1341. PubMed ID: 35907691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
    Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy.
    Picco G; Cattaneo CM; van Vliet EJ; Crisafulli G; Rospo G; Consonni S; Vieira SF; Rodríguez IS; Cancelliere C; Banerjee R; Schipper LJ; Oddo D; Dijkstra KK; Cinatl J; Michaelis M; Yang F; Di Nicolantonio F; Sartore-Bianchi A; Siena S; Arena S; Voest EE; Bardelli A; Garnett MJ;
    Cancer Discov; 2021 Aug; 11(8):1923-1937. PubMed ID: 33837064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies.
    Randrian V; Evrard C; Tougeron D
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-agnostic drug development in dMMR/MSI-H solid tumors.
    Bhamidipati D; Subbiah V
    Trends Cancer; 2023 Oct; 9(10):828-839. PubMed ID: 37517955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature.
    San-Román-Gil M; Martínez-Delfrade I; Albarrán-Fernández V; Guerrero-Serrano P; Pozas-Pérez J; Chamorro-Pérez J; Rosero-Rodríguez D; Sotoca-Rubio P; Barrill-Corpa AM; Alia-Navarro V; González-Merino C; García-de-Quevedo-Suero C; López V; Ruz-Caracuel I; Perna-Monroy C; Ferreiro-Monteagudo R
    Front Immunol; 2024; 15():1352262. PubMed ID: 38361927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
    Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
    JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency.
    Cohen R; Colle R; Pudlarz T; Heran M; Duval A; Svrcek M; André T
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33800202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.